Minerva Neurosciences | NERV - Przychody Ze Sprzedaży





Obroty Zmiana Data
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Adma Biologics USD 114.5M 24.66M 2026-03
ALKERMES USD 496.01M 103.1M 2026-06
Alterity Therapeutics Limited AUD 596.04K 584.66K 2025-12
AstraZeneca USD 15.38B 90M 2026-06
BioCryst Pharmaceuticals USD 218.25M 188.3M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Cipla INR 71.19B 5.78B 2026-06
Clal Biotechnology ILS 3.41M 2M 2022-12
Compugen USD 6.35M 60.98M 2026-03
CSL USD 8.33B 4.79B 2025-12
Eli Lilly USD 22.97B 3.17B 2026-06
GlaxoSmithKline GBP 8.41B 781M 2026-06
Grifols EUR 2B 306.7M 2026-03
Halozyme Therapeutics USD 481M 104M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
J&J USD 25.31B 1.21B 2026-06
Merck USD 16.6B 310M 2026-06
Minerva Neurosciences USD 0 0 2024-09
Neurocrine Biosciences USD 959M 148M 2026-06
Novartis USD 14.41B 1.3B 2026-06
Novavax USD 147.14M 76.69M 2025-12
Pfizer USD 15.03B 530M 2026-06
Roche Holding CHF 30.36B 14.71B 2026-06
Sanofi EUR 11.95B 710M 2026-06
Takeda JPY 1.22T 130B 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12